Rossari Biotech Ltd · NSE:ROSSARI
Rossari Biotech — Q3 FY2021 Earnings Presentation
14 slides from Rossari Biotech's earnings presentation, Jan 23, 2021
Slide 1: Exchange cover letter for Q3 FY21 earnings presentation
® ROSSARI making you more competitive January 23, 2021 DCS-CRD Listing Compliance BSE Limited National Stock Exchange oflndia Ltd. First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Phiroze Jeejeebhoy Towers Plot No.C/1, 'G'Block, Bandra- Kurla Complex Dalal Street, Fort Mumbai
Slide 2: Rossari Biotech Limited Q3 & 9M FY21 Results Presentation
Rossari Biotech Limited Q3 & 9M FY21 Results Presentation January 23, 2021
Slide 3: Disclaimer
Disclaimer Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Ltd (Rossari) in the presentation (“forward-looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to b
Slide 4: Q3 & 9M FY21 Results Overview
Q3 & 9M FY21 Results Overview 3
Slide 5: Q3 FY21 – Key Financial Highlights
Q3 FY21 – Key Financial Highlights Revenue from Operations EBITDA PAT (Rs. crore) (Rs. crore) (Rs. crore) 20.7 * 21.6 34.0 18.3 2.3 210.0 30.1 30.1 162.4 171.7 18.4 # Q3 FY20 Q2 FY21 Q3 FY21 Q3 FY20 Q2 FY21 Q3 FY21 Q3 FY20 Q2 FY21 Q3 FY21 29.3% Shift % (Y-o-Y) 13.0% Shift % (Y-o-Y) 18.0% Shift % (Y-
Slide 6: Management Message
Management Message Commenting on the performance for the quarter, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said “We have delivered a healthy performance during the quarter, registering a top-line growth of 29%. Our HP
Slide 7: Key Developments
Key Developments On-track to fully operationalise Greenfield manufacturing facility at Dahej by March 2021 The first phase of the unit, commissioned in the previous quarter, is fully operational The Greenfield facility will have a total installed capacity 132,500 MTPA, enhancing the total capaci
Slide 8: Consolidated P&L Statement
Consolidated P&L Statement Y-o-Y Change Y-o-Y Change Particulars (Rs. crore) Q3 FY21 Q3 FY20 9M FY21 9M FY20 (%) (%) Revenues from Operations 210.0 162.4 29.3% 491.1 440.5 11.5% Total Expenditure • Raw Material expenses 139.8 102.9 35.9% 311.6 272.8 14.2% • Employee benefits expense 10.9 10.1 7.9% 3
Slide 9: Q3 FY21 - Segment-wise Details
Q3 FY21 - Segment-wise Details Segment-wise Revenue Break-up (Rs. crore) HPPC TSC AHN 119.6 87.7 78.2 76.0 70.3 68.3 16.1 15.6 12.2 Q3 FY20 Q2 FY21 Q3 FY21 HPPC TSC AHN Shift (Y-o-Y) % 57.3% 11.2% -24.6% Shift (Q-o-Q) % 36.3% 14.5% -22.1% Key Highlights: The Company continued to witness strong mom
Slide 10: Q3 FY21 - Financial and Operational Discussions (Y-o-Y)
Q3 FY21 - Financial and Operational Discussions (Y-o-Y) Net Revenues Revenues from operations stood at Rs. 210.0 crore from Rs. 162.4 crore The Company is witnessing normalization in demand and enquiries across its businesses. While the HPPC business continued to report robust sales, the demand en
Slide 11: Annexure
ROSSARI making you more eompettive Annexure 10
Slide 12: Conference Call Details
Conference Call Details Q3 & 9M FY21 Earnings Conference Call Time • 06:00 p.m. IST on Monday, January 25, 2021 To enable participants to connect to the conference call without Pre-registration having to wait for an operator, please register at the below mentioned link: Primary dial-in number • + 91
Slide 13: About Us
About Us Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a For further information, please contact: Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Manasi Nisal Headquartered at Mumbai, India, the Company operates 2
Slide 14: Thank you
Thank y#u making you more eompettive